The Centre for Process Innovation has officially started building work on its £38m state-of-the-art biologics centre
The Centre for Process Innovation (CPI) will officially break ground on its state-of-the-art national biologics centre today.
The £38m National Biologics Manufacturing Centre (NBMC), in Darlington, will help strengthen the UK’s life-science sector by cutting risks involved in developing new bio-pharmaceutical products for companies.
Bio-pharmaceuticals is a growing market for vaccines and other medicines that are created by biological processes, not chemicals
Due for completion in 2015, the centre is part of the Government’s ‘Strategy for UK Life Sciences’.
CPI’s team of scientists, engineers and sector specialists will help companies of all sizes develop, demonstrate, prototype and scale-up their ideas.
It means new products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale, helping to speed up their route to market.
Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies and Sandy Anderson, OBE, Chair of Tees Valley Unlimited, attended the event.
Mr Bagshaw said: “The NBMC is an excellent opportunity to bring industry, academia and the funding agencies together to create the best possible environment for UK Biotechnology to grow.”
Sandy Anderson, OBE, Chair of Tees Valley Unlimited said the centre is an “excellent example of what can be achieved through genuine partnership”.
“The healthcare industry and CPI have worked closely with Darlington Council and TVU, the Local Enterprise Partnership for the Tees Valley, to make this investment in innovate technology possible.”
Bio-pharmaceuticals has grown steadily over the last decade.
It is currently being used by major companies to treat various forms of cancer and autoimmune diseases such as arthritis among others.
No comments:
Post a Comment